Sterling Capital Management LLC raised its position in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 25.4% in the first quarter, according to its most recent disclosure with the SEC. The firm owned 66,500 shares of the biopharmaceutical company’s stock after acquiring an additional 13,470 shares during the period. Sterling Capital Management LLC’s holdings in Gilead Sciences were worth $9,268,000 as of its most recent filing with the SEC.
A number of other large investors have also recently made changes to their positions in GILD. Aviva PLC grew its stake in shares of Gilead Sciences by 5.4% in the 4th quarter. Aviva PLC now owns 1,156,738 shares of the biopharmaceutical company’s stock worth $141,978,000 after acquiring an additional 59,782 shares in the last quarter. Nordea Investment Management AB lifted its position in shares of Gilead Sciences by 16.5% during the fourth quarter. Nordea Investment Management AB now owns 5,138,699 shares of the biopharmaceutical company’s stock valued at $630,056,000 after purchasing an additional 726,101 shares in the last quarter. Life Cycle Investment Partners Ltd purchased a new position in Gilead Sciences during the fourth quarter worth about $1,418,000. Beacon Investment Advisory Services Inc. grew its position in Gilead Sciences by 10.3% in the 4th quarter. Beacon Investment Advisory Services Inc. now owns 111,531 shares of the biopharmaceutical company’s stock worth $13,689,000 after purchasing an additional 10,449 shares in the last quarter. Finally, SageView Advisory Group LLC increased its stake in Gilead Sciences by 159.5% in the 3rd quarter. SageView Advisory Group LLC now owns 23,940 shares of the biopharmaceutical company’s stock valued at $2,657,000 after buying an additional 14,715 shares during the last quarter. 83.67% of the stock is owned by institutional investors.
Insider Buying and Selling at Gilead Sciences
In related news, insider Johanna Mercier sold 3,000 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $123.92, for a total transaction of $371,760.00. Following the sale, the insider directly owned 124,234 shares in the company, valued at approximately $15,395,077.28. This represents a 2.36% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $125.40, for a total transaction of $376,200.00. Following the completion of the transaction, the chief financial officer directly owned 171,646 shares of the company’s stock, valued at approximately $21,524,408.40. This trade represents a 1.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 68,000 shares of company stock valued at $8,930,150 over the last three months. 0.30% of the stock is currently owned by insiders.
Gilead Sciences News Roundup
- Positive Sentiment: Trodelvy won first-line approval in the U.S. and Europe for metastatic triple-negative breast cancer, opening a larger treatment market and improving Gilead’s oncology growth profile. Gilead Sciences (GILD) Wins First Line Trodelvy Approval In The US And Europe
- Positive Sentiment: Cantor Fitzgerald reiterated an Overweight rating and $155 price target after positive HIV trial results, signaling continued analyst confidence in Gilead’s pipeline and longer-term earnings potential. Cantor Fitzgerald Reiterates Overweight Rating on Gilead Sciences (GILD) Following Positive HIV Trial Results
- Positive Sentiment: Merck’s FDA announcement that KEYTRUDA combinations can be used with Trodelvy in first-line advanced TNBC adds another validation point for Trodelvy’s role in frontline cancer care. FDA Approves KEYTRUDA and KEYTRUDA QLEX each with Trodelvy as First-Line Treatment of Advanced Triple-Negative Breast Cancer
- Neutral Sentiment: Recent coverage also noted Gilead’s stock had been drifting lower before the approval news, reflecting recent market weakness rather than a change in fundamentals. Gilead Sciences (GILD) Dips More Than Broader Market: What You Should Know
Gilead Sciences Price Performance
Gilead Sciences stock opened at $127.86 on Friday. The business’s 50 day simple moving average is $130.19 and its 200 day simple moving average is $134.28. Gilead Sciences, Inc. has a 12 month low of $106.84 and a 12 month high of $157.29. The company has a market cap of $158.75 billion, a price-to-earnings ratio of 17.42 and a beta of 0.31. The company has a current ratio of 1.97, a quick ratio of 1.77 and a debt-to-equity ratio of 0.89.
Gilead Sciences (NASDAQ:GILD – Get Free Report) last released its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.91 by $0.12. The business had revenue of $6.96 billion during the quarter, compared to the consensus estimate of $6.91 billion. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The business’s revenue for the quarter was up 4.4% on a year-over-year basis. During the same period last year, the business posted $1.81 earnings per share. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Sell-side analysts forecast that Gilead Sciences, Inc. will post -0.8 EPS for the current year.
Gilead Sciences Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, June 29th. Shareholders of record on Monday, June 15th will be issued a dividend of $0.82 per share. The ex-dividend date of this dividend is Monday, June 15th. This represents a $3.28 annualized dividend and a yield of 2.6%. Gilead Sciences’s dividend payout ratio is 44.69%.
Analysts Set New Price Targets
GILD has been the topic of several recent analyst reports. Rothschild & Co Redburn dropped their target price on shares of Gilead Sciences from $170.00 to $167.00 in a research report on Monday, May 11th. Leerink Partners dropped their price target on Gilead Sciences from $148.00 to $146.00 in a report on Friday, May 8th. Cantor Fitzgerald reissued an “overweight” rating and issued a $155.00 price objective on shares of Gilead Sciences in a research report on Tuesday, June 16th. Citigroup upped their price objective on Gilead Sciences from $156.00 to $165.00 and gave the company a “buy” rating in a research note on Monday, April 13th. Finally, Wall Street Zen lowered Gilead Sciences from a “strong-buy” rating to a “hold” rating in a research report on Saturday, May 9th. Twenty-five analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, Gilead Sciences presently has a consensus rating of “Moderate Buy” and an average target price of $158.41.
Check Out Our Latest Stock Report on Gilead Sciences
About Gilead Sciences
Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.
Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.
Featured Articles
- Five stocks we like better than Gilead Sciences
- Rocket Lab’s NASA Win Tests Key Support After Sharp Pullback
- AST SpaceMobile Just Nailed a Major Launch—So Why Is the Stock Crashing?
- Palantir’s Valuation Problem Just Met 2 New Growth Catalysts
- Xcel Energy Stock Offers Stability as Electricity Demand Builds
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD – Free Report).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
